Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30409299 | 0.89 | TSHR (0.62) | TSHRALDH1A1LMNASIGMAR1HPGD | |
| SCHEMBL78754 | 0.89 | TSHR (0.62) | TSHRALDH1A1LMNASIGMAR1HPGD | |
| SCHEMBL27945832 | 0.85 | F2 (0.53) | ALDH1A1LMNASIGMAR1HPGDMEN1 | |
| SCHEMBL8867687 | 0.84 | TSHR (0.61) | TSHRALDH1A1LMNASIGMAR1HPGD | |
| SCHEMBL9627328 | 0.83 | MAOB (0.64) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1935375 | 0.83 | TSHR (0.69) | TSHRALDH1A1LMNASIGMAR1HPGD | |
| SCHEMBL6998770 | 0.83 | TSHR (0.59) | TSHRALDH1A1LMNASIGMAR1HPGD | |
| SCHEMBL7328646 | 0.83 | TSHR (0.59) | TSHRALDH1A1LMNASIGMAR1HPGD | |
| SCHEMBL81981 | 0.83 | TSHR (0.59) | TSHRALDH1A1LMNASIGMAR1HPGD | |
| SCHEMBL9172285 | 0.83 | TSHR (0.59) | TSHRALDH1A1LMNASIGMAR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024072178-A1 | COMPOUND FOR TARGETED PROTEIN DEGRADATION, AND USE THEREOF | (주)사이러스테라퓨틱스 | 2024-04-04 | — | — | WO | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| CN-101730677-B | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2014-07-16 | — | — | CN | disclosed |
| US-8765727-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765727-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| EP-1015441-A1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATIVES USEFUL AS PROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012919-A1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATES USEFUL AS PROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
| US-5686484-A | ANTHELMINTICS, ACARICIDES, INSECTICIDES | SANKYO CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| US-5428034-A | Insecticides, parasiticides, anthelmintics | SANKYO CO., LTD. (JP) | 1995-06-27 | — | — | US | disclosed |
| EP-0444964-B1 | Milbemycin ether derivatives, their preparation and their anthelmintic uses | SANKYO CO (JP) | 1994-10-26 | — | — | EP | disclosed |
| EP-0444964-A1 | Milbemycin ether derivatives, their preparation and their anthelmintic uses | Sankyo Company Limited (JP) | 1991-09-04 | — | — | EP | disclosed |
| EP-0162208-B1 | NOVEL N-SUBSTITUTED 3,4-DIHYDROPYRIMIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1989-11-23 | — | — | EP | disclosed |
| US-4683234-A | HYPOTENSIVE AGENTS, ANTI-ANGINA | SUNTORY LIMITED (JP) | 1987-07-28 | — | — | US | disclosed |
| EP-0162208-A2 | Novel N-substituted 3,4-dihydropyrimidine derivatives, processes for preparing them and pharmaceutical compositions | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, HRH2 | TSHR 2331/4885ALDH1A1 1304/4885LMNA 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.